World / Diabetes
Biodel To Report Results Of VIAject™ Pivotal Phase III Clinical Trials At EASD Conference
05.09.2008 06:17
medicalnewstoday.com
Biodel Inc. (Nasdaq: BIOD) announced that it will report results of its two pivotal Phase III clinical trials of VIAject™ in patients with Type 1 and Type 2 diabetes next week at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome. Two posters summarizing these results, #677 by Flacke et al.
World
Diabetes
Physicians Eager To Increase Their First- And Second-Line Prescriptions For Januvia Over The Next Two Years For The Treatment Of Type 2 Diabetes
05.09.2008 06:17
medicalnewstoday.com
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Merck's Januvia is currently prescribed most often as a third- or later-line of therapy for the treatment of type 2 diabetes.
World
Diabetes
OSI Pharmaceuticals Initiates Clinical Development Program For Anti-Diabetes Candidate, PSN821
05.09.2008 06:17
medicalnewstoday.com
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes. Discovered by OSI's diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in pre-clinical studies.
World
Diabetes
Blood 'Fingerprints' For Cancer
05.09.2008 06:17
medicalnewstoday.com
Serum microRNAs (miRNAs) can serve as biomarkers for the detection of diseases including cancer and diabetes, according to research published online this week in Cell Research. The findings pave the way for a revolutionary non-invasive diagnostic tool. miRNAs are a class of naturally occurring small non-coding RNAs that have been linked with cancer development.
World
Diabetes
English